EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Avacta committed to moving its tumor microenvironment activated drug conjugate into the clinic ahead of schedule. Testing in humans is due to start next year. Statement   

> Themis Bioscience secured up to $21 million (€19 million) in non-dilutive funding to support a phase 3 trial of its Chikungunya vaccine. Filings to start the trial are planned for later this year. Release  

> Merck KGaA published interim data from a phase 2 trial of tepotinib in non-small cell lung cancer. The trial linked the MET kinase inhibitor to a response rate of around 50%. Statement 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sotio’s autologous immunotherapy achieved a 15.5 month overall survival in stage 4 non-small cell lung cancer, as compared to 11.8 months in the control arm. Release 

> BerGenBio presented updated data from a trial of bemcentinib and low-intensity chemotherapy in elderly acute myeloid leukemia patients. About half of the subjects responded to the regimen. Statement   

> Corbin Therapeutics licensed neuroinflammation assets from the University of Dundee Drug Discovery Unit. Release  

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.